C4 Therapeutics (CCCC) Competitors $5.61 +0.28 (+5.25%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CCCC vs. ALEC, INBX, CGEN, RCUS, NTLA, EVO, SPRY, ARDX, TVTX, and XNCRShould you be buying C4 Therapeutics stock or one of its competitors? The main competitors of C4 Therapeutics include Alector (ALEC), Inhibrx (INBX), Compugen (CGEN), Arcus Biosciences (RCUS), Intellia Therapeutics (NTLA), Evotec (EVO), ARS Pharmaceuticals (SPRY), Ardelyx (ARDX), Travere Therapeutics (TVTX), and Xencor (XNCR). These companies are all part of the "pharmaceutical products" industry. C4 Therapeutics vs. Alector Inhibrx Compugen Arcus Biosciences Intellia Therapeutics Evotec ARS Pharmaceuticals Ardelyx Travere Therapeutics Xencor Alector (NASDAQ:ALEC) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation, community ranking and profitability. Which has more risk and volatility, ALEC or CCCC? Alector has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 3.04, suggesting that its share price is 204% more volatile than the S&P 500. Do analysts recommend ALEC or CCCC? Alector presently has a consensus price target of $17.75, indicating a potential upside of 253.59%. C4 Therapeutics has a consensus price target of $11.20, indicating a potential upside of 99.64%. Given Alector's stronger consensus rating and higher possible upside, equities analysts clearly believe Alector is more favorable than C4 Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alector 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00C4 Therapeutics 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Does the MarketBeat Community believe in ALEC or CCCC? Alector received 125 more outperform votes than C4 Therapeutics when rated by MarketBeat users. Likewise, 61.38% of users gave Alector an outperform vote while only 38.81% of users gave C4 Therapeutics an outperform vote. CompanyUnderperformOutperformAlectorOutperform Votes15161.38% Underperform Votes9538.62% C4 TherapeuticsOutperform Votes2638.81% Underperform Votes4161.19% Which has preferable valuation and earnings, ALEC or CCCC? Alector has higher revenue and earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlector$97.06M5.03-$130.39M-$1.80-2.79C4 Therapeutics$20.76M18.74-$132.49M-$1.90-2.95 Does the media prefer ALEC or CCCC? In the previous week, C4 Therapeutics had 8 more articles in the media than Alector. MarketBeat recorded 10 mentions for C4 Therapeutics and 2 mentions for Alector. Alector's average media sentiment score of 0.83 beat C4 Therapeutics' score of 0.61 indicating that Alector is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive C4 Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Is ALEC or CCCC more profitable? Alector has a net margin of -290.66% compared to C4 Therapeutics' net margin of -367.17%. C4 Therapeutics' return on equity of -44.60% beat Alector's return on equity.Company Net Margins Return on Equity Return on Assets Alector-290.66% -102.63% -25.70% C4 Therapeutics -367.17%-44.60%-28.98% Do insiders and institutionals have more ownership in ALEC or CCCC? 85.8% of Alector shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 9.1% of Alector shares are owned by company insiders. Comparatively, 8.6% of C4 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryAlector beats C4 Therapeutics on 14 of the 18 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get C4 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CCCC vs. The Competition Export to ExcelMetricC4 TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$389.00M$3.15B$5.54B$8.53BDividend YieldN/A1.77%5.13%4.14%P/E Ratio-2.9511.73114.8115.14Price / Sales18.74397.851,495.55100.10Price / CashN/A148.6639.6734.08Price / Book1.384.024.665.02Net Income-$132.49M-$42.25M$119.06M$225.46M7 Day Performance-4.75%8.04%0.80%0.37%1 Month Performance3.31%8.69%5.65%3.57%1 Year Performance300.71%32.09%36.75%29.43% C4 Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CCCCC4 Therapeutics2.2288 of 5 stars$5.61+5.3%$10.50+87.2%+325.0%$389.00M$20.76M-2.95150Upcoming EarningsNews CoveragePositive NewsALECAlector4.1844 of 5 stars$5.10+0.6%$17.75+248.0%-8.1%$496.34M$55.28M-2.83270Upcoming EarningsPositive NewsINBXInhibrx3.7081 of 5 stars$16.29+1.2%$27.00+65.7%+0.1%$235.81M$1.69M0.00166CGENCompugen2.1965 of 5 stars$1.64-1.8%$4.00+143.9%+125.0%$146.35M$42.72M-16.4068Positive NewsRCUSArcus Biosciences2.7286 of 5 stars$15.98-2.6%$33.67+110.7%-2.0%$1.46B$247M-5.17500Upcoming EarningsNTLAIntellia Therapeutics4.2672 of 5 stars$14.33-4.4%$59.13+312.7%-41.9%$1.46B$36.28M-2.61600High Trading VolumeEVOEvotec2.5238 of 5 stars$3.96+1.0%$5.93+49.8%-54.8%$1.40B$788.44M0.005,061Upcoming EarningsSPRYARS Pharmaceuticals2.8441 of 5 stars$14.27-5.9%$24.00+68.2%+328.7%$1.38B$30,000.00-30.3690ARDXArdelyx4.1613 of 5 stars$5.89-2.0%$11.67+98.1%+54.6%$1.37B$210.00M-21.81267Analyst ForecastInsider SellingOptions VolumeTVTXTravere Therapeutics2.1449 of 5 stars$17.76-3.4%$21.38+20.4%+161.5%$1.36B$177.64M-9.44460Earnings ReportAnalyst ForecastGap UpXNCRXencor4.0946 of 5 stars$21.02-2.5%$34.78+65.5%+21.7%$1.30B$133.62M-7.27280Upcoming Earnings Related Companies and Tools Related Companies Alector Competitors Inhibrx Competitors Compugen Competitors Arcus Biosciences Competitors Intellia Therapeutics Competitors Evotec Competitors ARS Pharmaceuticals Competitors Ardelyx Competitors Travere Therapeutics Competitors Xencor Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CCCC) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
